Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Ionis stock jumped Thursday after a Food and Drug Administration panel offered a mixed view of its Biogen (BIIB)-partnered treatment for a deadly neurodegenerative condition. X The companies are hoping to win approval for tofersen, a potential treatment for a rare form of ALS, or amyotrophic…
#ionis #biogen #als #lougehrig #ionispharmaceuticals #ions #sod1 #fda #svbsecurities #marcgoodman